Trinity Biotech plc each representing 4 A Ordinary Shares (TRIB) News
Filter TRIB News Items
TRIB News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
TRIB News Highlights
- TRIB's 30 day story count now stands at 3.
- Over the past 9 days, the trend for TRIB's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about TRIB are DEC.
Latest TRIB News From Around the Web
Below are the latest news stories about TRINITY BIOTECH PLC that investors may wish to consider to help them evaluate TRIB as an investment opportunity.
Trinity Biotech Announces It Has Begun Shipments of Its New HIV Screening Test, TrinScreen HIV to KenyaDUBLIN, Ireland, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announces it has begun commercial shipments to Kenya of its new rapid HIV screening test, TrinScreen HIV. The Kenyan HIV screening programme is one of the largest in Africa, with an estimated 10 million HIV screening tests performed annually. The Company has begun commercial |
Trinity Biotech Announces Management ChangesJohn Gillard Named Chief Executive OfficerDes Fitzgerald Named Interim Chief Financial Officer DUBLIN, Ireland, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the promotion of John Gillard, our Chief Financial Officer, to President and Chief Executive Officer, effective immediately. Des Fitzgerald, who has served as Director of |
Trinity Biotech plc (NASDAQ:TRIB) Held Back By Insufficient Growth Even After Shares Climb 31%Those holding Trinity Biotech plc ( NASDAQ:TRIB ) shares would be relieved that the share price has rebounded 31% in... |
Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held SharesDUBLIN, Ireland, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of diagnostic solutions for the point-of-care and clinical laboratory markets, today announced that on November 21, 2023 the Company received notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with the minimum market value of publicly held shares ("MVPHS") requirement set forth in the Nasdaq Listing Rules. |
Trinity Biotech Welcomes The Decision Of The High Court Of Kenya To Strike Out The Applications To Prevent the Procurement of TrinScreen HIV By The Kenyan Ministry of HealthDUBLIN, Ireland, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, welcomes the recent decision by the High Court of Kenya. The court has struck out both the interim application and the entire lawsuit filed by Gamma Zenith Kenya Limited against Trinity Biotech, Radiance Pharmaceutical, the Kenyan Ministry of Health, and the Kenyan Attorney General |
Trinity Biotech plc (NASDAQ:TRIB) Just Reported Earnings, And Analysts Cut Their Target PriceThere's been a notable change in appetite for Trinity Biotech plc ( NASDAQ:TRIB ) shares in the week since its... |
Trinity Biotech plc (NASDAQ:TRIB) Q2 2023 Earnings Call TranscriptTrinity Biotech plc (NASDAQ:TRIB) Q2 2023 Earnings Call Transcript October 3, 2023 Trinity Biotech plc misses on earnings expectations. Reported EPS is $-0.15 EPS, expectations were $-0.07. Operator: Good day, and welcome to Trinity Biotech Announces Second Quarter Financial Results. All participants will be in listen-only mode. [Operator Instructions] After today’s presentation, there will be […] |
Trinity Biotech Announces Q2 2023 Financial ResultsDUBLIN, Ireland, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the Company’s results for the quarter ended June 30, 2023. Summary Highlights: Revenue: Total revenue for fiscal Q2, 2023 was $13.9m (excluding Fitzgerald Industries, which was disposed of in April 2023). Excluding our Covid focused PCR Viral Transport Media (“VTM”) products and Fi |
Trinity Biotech plc to Announce Second Quarter Fiscal Year 2023 Financial ResultsConference Call Scheduled for October 3, 2023 at 11:00 am EASTERNDUBLIN, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the second quarter fiscal year 2023 on Tuesday, October 3, 2023. The Company has scheduled a conference call for that same day, Tuesday, October 3, 2023 at 11:00am ET (4:00pm BST) to discuss the results of t |
Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Minimum Bid Price RequirementDUBLIN, Ireland, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of diagnostic solutions for the point-of-care and clinical laboratory markets, today announced that on September 8, 2023 the Company received notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with Nasdaq Listing Rule 555(a)(2), as the minimum bid price of the Company’s American depositary shares (“ADSs”) |